LAS VEGAS — Adults with osteoporosis prescribed the antiresorptive denosumab were no more likely to sustain an atypical femur fracture compared with bisphosphonate users over 4 years, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results